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Abstract
Objectives—A family of histone deacetylases (HDACs) mediates chromatin remodeling, and
repression of gene expression. Deacetylation of histones within the HIV-1 long terminal repeat
(LTR) by HDACs plays a key role in the maintenance of latency, whereas acetylation of histones
about the LTR is linked to proviral expression and escape of HIV from latency. Global HDAC
inhibition may adversely affect host gene expression, leading to cellular toxicities. Potent
inhibitors selective for HDACs that maintain LTR repression could be ideal antilatency
therapeutics.
Methods—We investigated the ability of selective HDAC inhibitors to de-repress the HIV-1
LTR in both a cell line model of latency and in resting CD4+ T cells isolated from patients who
were aviremic on antiretroviral therapy (ART).
Results—We found that inhibition of class I HDACs increased acetylation of histones at the
LTR, but that LTR chromatin was unaffected by class II HDAC inhibitors. In a latently infected
cell line, inhibitors selective for class I HDACs were more efficient activators of the LTR than
inhibitors that target class II HDACs. Class I HDAC inhibitors were strikingly efficient inducers
of virus outgrowth from resting CD4+ T cells of aviremic patients, whereas HIV was rarely
recovered from patient’s cells exposed to class II HDAC inhibitors.
Conclusions—Further development of selective HDAC inhibitors as part of a clinical strategy
to target persistent HIV infection is warranted.
Keywords
histone deacetylase; HIV; latency; long terminal repeat; resting CD4+ T cells
© 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
Correspondence to: David M. Margolis, University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Ctr., CB#7435
Chapel Hill, NC 27599-7435, USA. Tel: +1 919 966 6388; fax: +1 919 966 0584; dmargo@med.unc.edu.
NIH Public Access
Author Manuscript
AIDS. Author manuscript; available in PMC 2013 October 28.
Published in final edited form as:














Latent infection of resting CD4+ T cells is established early during HIV-1 infection, making
eradication of HIV unachievable with current ART [1–3]. Following integration of viral
DNA into the cellular genome, the HIV long terminal repeat (LTR) promoter can revert to
transcriptional silence in the absence of stimulation [4–6]. One of the mechanisms through
which HIV latency is maintained is by the action of histone deacetylases (HDACs) at the
HIV-1 LTR (reviewed in [7]).
Histone deacetylases are lysine deacetylases that modify histones and induce transcriptional
repression, but can also exert influences on cellular activities that are independent of
transcriptional repression (reviewed in [8]). HDACs are generally divided into three classes.
The class I HDACs comprise HDAC1, 2, 3 and 8, whereas class II HDACs include 4, 5, 7
and 9 (subclass IIa) and 6 and 10 (subclass IIb). The catalytic domain of HDAC11 shares
homology with both class I and II and this enzyme is sometimes classified as a class IV
HDAC. The class III HDACs, the sirtuins, differ from the other classes in that they require
nicotinamide adenine dinucleotide (NAD) to function and are not affected by HDAC
inhibitors active against class I, II and IV.
Histone deacetylases repress transcription mainly through their ability to covalently modify
the lysine tail of core histones of nucleosomes through deacetylation. Deacetylation of lysine
residues on histone tails decreases the access of transcription factors to the DNA, and
recruits other histone-modifying complexes that result in further transcriptional repression.
In tissue culture models of latent HIV infection, HDAC1 is recruited to the LTR by multiple
DNA-binding complexes. HDAC1 recruitment by the transcription factor SV40 late specific
factor (LSF) in concert with YY1 was the first mechanism reported [9]. Later studies
suggested that AP-4 [10], heterodimers of the activation domain-deficient NFκB p50
subunit [11], C-myc through interaction with Sp1 [12], and CBF-1 by binding near the
NFκB/NFAT enhancer element [13] could also recruit HDAC1. CTIP2 was reported to
recruit HDAC1 or HDAC2 to the Sp1-binding site of the LTR [14]. Finally, it has been
suggested that HDAC3 associates with the LTR [15].
Disruption of HDAC1 recruitment to the LTR by specific DNA-binding molecules, or
inhibition of HDAC activity by global HDAC inhibitors leads to LTR activation and the
escape of HIV from latency in both cell line models and primary cells obtained from patients
[9,16,17]. Furthermore, the HDAC inhibitors (HDACis) valproic acid (VPA) and
suberoylanilide hydroxamic acid (SAHA; vorinostat) induce viral outgrowth from resting
CD4+ T cells of aviremic HIV-infected individuals on ART [18,19]. HDAC2 and 3 can also
occupy a site at the HIV LTR, and may play a role in the repression of LTR expression
[14,15]. These observations have led to the investigation of HDAC inhibition as a putative
therapeutic strategy to induce HIV from latency.
As global HDAC inhibition may have adverse effect on host cells, we studied the ability of
selective HDAC inhibitors to de-repress the HIV LTR in both a cell line model of latency
and in CD4+ resting T cells isolated from aviremic patients on ART. We found that
inhibitors that target class I HDACs 1, 2, 3 alone or in tandem with the class II HDAC6
were efficient inducers of HIV expression, yielding the outgrowth of replication-competent
HIV from the resting CD4+ cells of patients. However, inhibition of HDAC6 alone, or of
other class II HDACs resulted in marginal LTR activation in cell line systems, and did not
result in significant recovery of virus from patient’s cells. Of note, a selective inhibitor
targeting HDAC1 and 2 was not very effective at inducing LTR activation in cell lines and
virus outgrowth from resting CD4+ T cells of HIV-infected individuals. These findings
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J89 cells, a latently infected Jurkat cell line encoding the enhanced green florescence protein
(EGFP) as a marker for Tat-driven HIV LTR expression (gift of D.N. Levy) [20], were
grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (Sigma, St Louis,
Missouri, USA), 100 U/ml penicillin and 100 ug/ml of streptomycin (Invitrogen, Carlsbad,
California, USA) at 37°C under 5% CO2. Hela P4/R5 cells, a variant of HeLa Magi cells
expressing both CXCR4 and CCR5 selected for low background beta-galactosidase
expression via the HIV 1 minimal LTR (generous gift of N. Landau) [21], were cultured in
Phenol Red-free DMEM (Invitrogen) supplemented with 10% fetal bovine serum, 0.5 mg/ml
Puromycin (Sigma), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen).
High-throughput screening of LTR-activating compounds
Hela P4/R5 cells were seeded at 2000/well in 1536-well plates and incubated for 24 h. Test
compounds were added and cells were incubated an additional 24 h and β-galactosidase
activity was measured by the use of the Tropix Gal-Screen Assay Kit (Applied Biosystem,
Foster City, California, USA) and read with the Perkin Elmer Envision 2101 Multilabel
Luminometer.
Selective histone deacetylase inhibitors
The nonselective inhibitor valproic acid was obtained from Bedford Laboratories (Bedford,
Ohio, USA). Other inhibitors were synthesized at Merck Research Laboratories. MRK1 is a
selective inhibitor of the class I HDACs 1, 2, 3 and the class II HDAC6 [22]. MRK 4,
apicidin and MRK 13 are selective against HDACs 1, 2 and 3 [22,23]; MRK 10 is a
selective inhibitor of HDAC6 [24]. MRK 11 and MRK 14 selectivity inhibit the class II
HDACs 4, 5, 6, and 7 and the class I HDAC8 [25,26]. However, siRNA knockdown of
HDAC8 does not induce HIV LTR expression (A. Espeseth, unpublished observations).
MRK 12 is a selective inhibitor of HDACs 1 and 2 [22]. See Table 1.
Flow cytometry
J89 cells were washed with phosphate-buffered saline (PBS) and incubated overnight with
the indicated concentration of HDACi. Cells were washed and resuspended in PBS
containing 2% paraformaldehyde. GFP expression was measured by FACScan (Becton
Dickinson, San Jose, California, USA), and analyzed using Cell Quest software (Macintosh,
Sunnyvale, California, USA). Live cells were gated and two-parameter analysis used to
differentiate GFP-associated fluorescence from background fluorescence. A total of 10 000
gated events were collected and data represent the percentage of GFP-expressing cells in
total gated events.
Cytotoxicity assay
J89 cells were washed with PBS and incubated for 24 h in various concentrations of
inhibitors. To measure proliferation and viability in the presence of drugs, cells were
subjected to an MTT assay using a cell proliferation kit following the manufacturer’s
instructions (Roche Applied Sciences, Indianapolis, Indiana, USA). The percentage of cells
proliferating was calculated from cells cultured in drug-free medium.
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Chromatin immunoprecipitation (ChIP) assays were performed as previously described [19]
with the following modifications: J89 cells were cultured with HDACi at indicated
concentrations for 4 h. Formaldehyde crossed-linked cells were lyzed for 20 min on ice
using SDS Lysis buffer (Millipore, Billerica, Massachusetts, USA) and sonicated to
fragment chromatin to 500–1000 base pairs. 1 × 106 sonicated cells were used to set up each
immunoprecipitation reaction using 5 µg of antiacetyl histone 3 (Ac-H3, Millipore) or rabbit
preimmune immunoglobulin G (Sigma). PCR on immunoprecipitated or input DNA was
performed as described previously [19]. The percentage of input HIV LTR DNA was
determined by comparing the cycle threshold values of each reaction to a standard curve
generated from input DNA. The fold enrichment of acetylated histone proteins at the HIV-1
LTR region was calculated as a ratio of specific signal over untreated background signal.
Limiting dilution cultures of latently infected CD4+ T cells from HIV-infected donors
Lymphocytes were obtained by continuous-flow leukopheresis. Isolation of resting CD4+ T
cells, recovery and quantification of replication-competent virus were performed as
previously described [27]. For phytohemagluttinin (PHA) conditions, 93.6 million resting
CD4+ T cells were plated in replicate dilutions of 2.5 million (36 cultures), 0.5 million (six
cultures) and 0.1 million (six cultures) cells per well and stimulated with 1 µg/ml PHAL
(Remel, Lenexa, Kansas, USA), a five-fold excess of allogeneic irradiated peripheral blood
mononuclear cells (PBMCs) from a seronegative donor, and 20U/ml IL-2 for 24 h. For
MRK HDACi, 33.5–48.6 million resting CD4+ T cells were plated in replicate dilutions of
2.5 million (12–18 cultures), 0.5 million (six cultures) and 0.1 million (six cultures) cells per
well and stimulated with the indicated concentration of drugs for 24 h.
After maximum mitogen stimulation or drug exposure, cells were washed and cultured as
previously described [27].Culture supernatants were collected on days 15 and 19 and
assayed for virus production by p24 antigen capture ELISA (Zeptometrix, Buffalo, New
York, USA). Cultures were scored as positive if p24 was detected at day 15 and was
increased in concentration at day 19. A maximum likelihood method was used to calculate
the infectious units per million (IUPM) of resting CD4+ T cells after exposure to PHA, or
HDACi. If all cultures were negative, the IUPM was estimated to have a value lower than if
1 culture of 2.5 million cells had been positive.
Results
Histone deacetylase 1 potency corresponds with activation of the long terminal repeat
To screen for novel HDACis that induce expression of the HIV-1 promoter, candidate
HDAC inhibitors from the Merck Research Laboratories chemical library were tested for the
ability to up-regulate LTR expression in the P4/R5 LTR reporter cells [21]. As shown in Fig.
1a, by Spearman’s rank correlation there was a significant (P<0.0001) association between
inhibitory potency against HDAC1 as measured in an in-vitro enzymatic assay, and
increasing efficiency in LTR induction.
Class I but not class II inhibitors induce chromatin changes at the HIV long terminal repeat
leading to long terminal repeat expression
Class I HDACs have been shown to maintain histones within the nucleosome-bound
provirus in a hypoacetylated state, facilitating LTR repression [9–15]. Conversely,
acetylation of histones by histone acetyltransferases (HATs) leads to neutralization of the
net charge on lysine residues, increasing the access of transcription complexes to chromatin
and recruiting other chromatin remodeling complexes, thus abrogating HDAC-mediated
repression. However, the contribution of class II HDACs to this equilibrium is unexplored.
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We therefore compared the ability of class I and class II selective HDAC inhibitors (Table
1) to induce acetylation of nucleosome 1 (Nuc 1) of the HIV LTR by performing chromatin
immunoprecipitation in J89 cells. Precipitated DNA was quantified using a set of primers
spanning the Nuc 1 region of the HIV promoter. Cells were assayed after only 4 h of
treatment to minimize the impact of indirect, secondary effects that may follow histone
deacetylation. The percentage of input for each immunoprecipitation was calculated and the
relative fold occupancy of acetylated histones reported. We found that class I but not class II
inhibitors induce acetylation of histones at the HIV-LTR (Fig. 1b).
Class I selective histone deacetylase inhibitors are better than class II at inducing long
terminal repeat expression
To determine the ability of selective HDAC inhibitors to induce HIV expression, selected
candidate compounds were tested in the J89 Jurkat T cell model of HIV latency [20] and
LTR-driven EGFP reporter gene expression measured.
Class I selective HDAC inhibitors, MRK 1, MRK 4 and Apicidin all induced LTR activation
(Fig. 1c). As expected, the weak, nonselective HDAC inhibitor VPA also effectively
induced LTR expression, albeit at millimolar concentrations. However, little LTR
expression was induced by the class II HDAC inhibitors MRK 10, MRK 11 and MRK 14.
This was not due to toxicity of VPA or MRK 10, 11 and 14, as concentrations used to
induce LTR expression did not perturb cell proliferation (Fig. 1d and ref. [18]). These
compounds were also evaluated in the HIV latency model cell lines AcH2, J1.1 and Hela P4/
R5. A similar observation was made where only the class I and nonselective inhibitors
robustly induced LTR expression (data not shown).
Class I selective histone deacetylase inhibitors induce viral outgrowth more efficiently
than class II histone deacetylase inhibitors
We next examined the ability of the various HDACis to induce viral outgrowth from the
resting CD4+ T cells of HIV-infected volunteers. Resting CD4+ T cells were isolated by
negative selection from a total of 14 aviremic HIV-infected patients on ART (stable HIV-1
plasma RNA <50 copies/ml). Resting cells were obtained at multiple time points from six of
the patients. The frequency of viral recovery after HDACi exposure in multiple limiting-
dilution culture assays was compared to that after maximum mitogen activation with PHA,
allogenic PBMCs, and IL-2. As observed in J89 cells, the class I HDAC inhibitor MRK 1
allowed more frequent recovery of replication-competent HIV from patient’s resting CD4+
T cells than the class II selective inhibitors, MRK 10 and MRK11 (Fig. 2). Of note, in seven
of eight patients studied, there was less than a two-fold difference in the frequency of
recovery of HIV in cells exposed to MRK 1 compared to PHA, a difference that is within
the variance of our resting cell outgrowth assay.
The nonselective inhibitor VPA was also effective at inducing virus from resting CD4+ T
cells of aviremic HIV+ patients (Fig. 2), as previously demonstrated [18,19]. The surprising
activity of VPA in primary cells as compared to more potent and specific HDAC inhibitors
is not well understood, but could be the result of effects of VPA on other cellular enzymes,
such as glycogen synthase kinase-3β.
However, whereas the class I inhibitors Apicidin and MRK4, were effective at inducing
LTR expression in J89 cells (Fig. 1c), induction of virus from CD4+ resting T cells by these
inhibitors was suboptimal (Fig. 3). As both MRK 4 and Apicidin appear to be slightly
antiproliferative in J89 T cells (Fig. 1d), we cannot rule out the possibility that such an effect
limits the recovery of virus in resting CD4+ T-cell outgrowth assays.
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As global HDAC inhibition may have effects on the host cell that lead to toxicities and
adverse clinical outcomes, potent but selective inhibition of HDACs required to maintain
LTR repression is desirable for potential therapeutics designed to disrupt HIV latency. MRK
4 and Apicidin are both selective against HDAC1–3, induce LTR expression (Fig. 1c), but
may weakly induce viral outgrowth in patients’ cells due to effects on the host cell (Fig. 3).
To study the effect of HDACi selective for HDACs 1–3 that are without apparent host cell
toxicity, we studied two additional compounds with selectivity against HDAC1 and 2 (MRK
12) and HDAC1, 2, and 3 (MRK 13). Although activation of LTR expression in the J89 cell
line by MRK 13 (which inhibits HDAC1–3) was comparable to that of MRK1 (which
inhibits HDAC1–3 and 6; Fig. 4a), in six of the seven patients studied, recovery of HIV
from cells exposed to MRK 13 was over three-fold less frequent than from cells exposed to
PHA (Fig. 4b and c). Surprisingly, the HDAC1 and 2 inhibitors, MRK 12 performed poorly
in both cell line and primary resting CD4+ T-cell assays (Fig. 4a and c).
Discussion
Selective HDAC inhibitors induce expression of the HIV promoter and allow recovery of
replication-competent HIV from the resting CD4+ T cells of ART-treated, aviremic patients.
Inhibition of class I but not class II HDACs resulted in an increase of acetylated histones at
the nucleosome-bound LTR. We found that inhibitors that target the class I HDACs 1, 2 and
3 were more efficient activators of the HIV LTR in a cell line model of HIV latency than
inhibitors that target the class II HDACs. Class II HDAC inhibitors also performed poorly at
inducing virus outgrowth from resting CD4+ T cells isolated from aviremic HIV+ patients.
MRK 12, an inhibitor selective against HDAC1 and 2 failed to activate the LTR in a cell
line model of latency, and also poorly induced virus outgrowth from resting CD4+ T cells.
This finding is surprising given prior studies illustrating HDAC1, and to a lesser extent
HDAC2, activity at the HIV-1 LTR. However, our studies are the first to utilize selective
inhibitors. HDAC1 and 2 associate with the Sin3, NuRD or CoREST corepressor complexes
to repress transcription (reviewed in [28]). It seems likely that HDACs 1, 2, and 3 cooperate
as part of one or more multiprotein complexes to mediate HIV LTR repression.
HDAC3 is found in complex with the nuclear hormone corepressors NCoR/SMRT. Whereas
HDAC1 and 2 are reported to be global transcription repressors, HDAC3 is reported to be a
more specific repressor with activity against genes involved in nuclear receptor signaling
(reviewed in [28]). HDAC3 is reported to occupy a site at the HIV promoter and may play a
role in suppressing transcription [15].
We investigated the ability of four inhibitors (MRK 1, MRK 4, Apicidin and MRK 13)
targeting HDACs 1, 2 and 3 to induce virus outgrowth from resting CD4+ T cells. Although
all four compounds induced LTR transcription in J89 cells, only MRK 1 robustly induced
virus outgrowth from resting CD4+ T cells. In addition to its selectivity for HDAC1, 2, and
3, this inhibitor also targets HDAC6. However, it should be noted that HDAC6 inhibition
alone has little effect on HIV LTR expression, as demonstrated (Figs 1c and 2) by an
inhibitor selective for HDAC6 (MRK 10). Of note, inhibition of HDAC6 may only be
relevant in the study of patient’s cells, as inhibition of HDAC1, 2, and 3 is as effective in
inducing LTR expression as inhibition of HDAC1, 2, 3 and 6 in J89 cells. Interestingly, one
study reported a predominantly cytoplasmic localization of HDAC6 in transformed,
cancerous cells and a mostly nuclear localization in normal cells [29]. However, as HDAC6
does not appear to act directly at the HIV LTR [30], we speculate that the ability of Merck 1
to inhibit HDAC6 contributes to the outgrowth of virus from primary cells at another step in
the viral lifecycle, or via other effects on the infected cell.
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The mechanism by which HDAC6 might contribute to the suppression of the HIV
expression requires further study. HDAC6 is a predominantly cytoplasmic enzyme, but can
shuttle to the nucleus and is reported to mediate promoter repression in certain systems [29].
For example, NF-κB p50 and p65 cooperate with HDAC6 to repress transcription of the H+-
K+-ATPase gene [31]. Runt-related transcription factor 2 mediates repression of the p21
promoter via its interaction with HDAC6 [32]. In yet another example of HDAC6-mediated
repression, the enzyme binds to a domain of the HAT p300 leading to repression of its
transcriptional activities. HDAC inhibition or siRNA knockdown of HDAC6 ablate this
p300-mediated repression [33]. Regardless of the role HDAC6 may be playing in LTR
repression, defining the mechanisms involved may provide additional targets for antilatency
therapies.
Despite potent antiretroviral therapy, chronic HIV infection remains a formidable problem
that requires novel approaches. These findings suggest that selective HDAC inhibitors may
contribute to therapeutic efforts to clear persistent HIV infection.
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Fig. 1. Class I and nonselective HDAC inhibition induces LTR expression more effectively than
class II HDAC inhibitors
(a) HIV LTR expression is increased by HDAC inhibitors with increasing inhibitory
potential for HDAC1. Hela P4/R5 cells were seeded and incubated for 24 h, followed by
addition of HDAC inhibitors. β-galactosidase activity was measured after 24 h incubation
with inhibitors. LTR activation is reported as the percentage β-galactosidase activity in
treated cells over untreated control. (b) Class I but not class II HDAC inhibitors increase
acetylation of Nuc1 at the HIV-1 LTR. J89 cells were treated with media, or HDAC
inhibitors: MRK 1 or MRK 13 at class I HDAC1 IC50 (500 nmol/l and 300 nmol/l,
respectively), MRK 10 or MRK 11 at class II HDAC4 IC50 (200 nmol/l and 500 nmol/l,
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respectively). Cells were treated for 4 h and assayed by chromatin immunoprecipitation with
control rabbit IgG or anti-acetylated H3. DNA products of ChIP were quantitated in
triplicate by real-time PCR. Assays are representative of three independent experiments, and
real-time quantitation of the fold change relative to untreated control is shown. Only class I
inhibitors demonstrate significant increases in histone H3 acetylation. (c) Class I and
nonselective HDAC inhibition induces HIV expression. J89 cells were incubated overnight
with the indicated concentrations of the HDACi. LTR-driven GFP production was measured
by flow cytometry as described in methods. The data presented are the mean ± SE of three
independent experiments. (d) Toxicity of HDAC inhibitors on J89 cells at concentrations
used to measure promoter activation. J89 cells were cultured in the absence or presence of
the indicated inhibitors for 24 h at the concentrations displayed. 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed in triplicate. The
percentage of proliferating cells was calculated compared to cells cultured in standard
media. ChIP, chromatin immunoprecipitation; GFP, green florescence protein; HDAC,
histone deacetylase; LTR, long terminal repeat.
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Fig. 2. Recovery of replication-competent HIV from the resting CD4+ T cells of aviremic patients
treated with HDAC inhibitors: MRK 1 (class I HDACs 1, 2, and 3 and class II HDAC6), VPA
(nonselective), or MRK 10 or 11 (class II HDACs)
Patient cells were subjected to maximum mitogen stimulation or exposed to 2 µmol/l MRK
1, 40 µmol/l VPA, 2 µmol/l MRK 10 and 10 µmol/l MRK 11 for 24 h. Cells were washed
and co-cultured with CD8-depleted PBMC as detailed in methods. Frequency of virus
outgrowth from cells treated with HDACi was compared to the frequency of outgrowth from
maximally stimulated cells (PHA). Each icon represents independent studies of patient cell
samples; patient samples were simultaneously tested with mitogen or HDACi on the same
day. Dashed lines indicate the limit of detection of the assay. HDAC, histone deacetylase;
PBMC, peripheral blood mononuclear cell; VPA, valproic acid.
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Fig. 3. Recovery of replication-competent HIV from resting CD4+ T cells of aviremic patients
treated with Apicidin and MRK 4, inhibitors selective only for the class I HDACs 1, 2, and 3.
Patient cells were subjected to maximum mitogen stimulation or exposed to 4 µmol/l MRK 4 or 1
µmol/l MRK 6 for 24 h
Cells were washed and co-cultured with CD8-depleted PBMC as described in methods.
Frequency of virus outgrowth from cells treated with HDACi was compared to outgrowth
after maximal mitogen activation by PHA. Each icon represents independent studies of
patient cell samples; patient samples were simultaneously tested with mitogen or HDACi on
the same day. Dashed lines indicate the limit of detection of the assay. HDAC, histone
deacetylase; PBMC, peripheral blood mononuclear cell.
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Fig. 4. HIV expression and outgrowth is induced by inhibitors targeting HDACs 1, 2, and 3, but
viral outgrowth is markedly improved by the tandem inhibition of HDAC1–2 and the class II
HDAC6
(a) J89 cells were incubated overnight with 1 µmol/l MRK 1 (selective for HDAC1, 2, 3 and
6), 2–20 µmol/l MRK 12 (HDAC1 and 2) or 200 nmol/l MRK 13 (HDAC1, 2, 3). LTR-
driven GFP production was measured by flow cytometry as described in methods. The data
presented are the mean ± SE of three independent experiments. (b) Resting CD4+ T cells
from patients were subjected to maximum mitogen stimulation or exposed to 200–300 nmol/
l MRK 13 for 24 h. Cells were washed and co-cultured with CD8-depleted PBMC as
described in methods. Frequency of virus outgrowth from cells treated with MRK 13 was
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compared to outgrowth after maximal mitogen activation. Each icon represents independent
studies of patient cell samples; patient samples were simultaneously tested with mitogen or
HDACi on the same day. Dashed lines indicate the limit of detection of the assay. (c)
Frequency of virus outgrowth from resting CD4+ T cells of aviremic HIV+ patients exposed
to 2 µmol/l MRK 1, 2–20 µmol/l MRK 12 and 300 nmol/l MRK 13 are shown as a
percentage of outgrowth obtained from corresponding maximal mitogen activation by PHA.
MRK 1, n = 8; MRK 12, n = 2; MRK 13, n = 7. GFP, green florescence protein; HDAC,
histone deacetylase; LTR, long terminal repeat; PBMC, peripheral blood mononuclear cell.
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Table 1
Selectivity of novel HDAC inhibitors.
HDACi Selectivity
MRK1 HDAC1, 2, 3 and 6
VPA Nonselective
MRK 4 HDAC1, 2, 3
Apicidin HDAC1, 2, 3
MRK 10 HDAC6
MRK 11 HDAC4, 5, 6, 7, 8
MRK 12 HDAC1, 2
MRK 13 HDAC1, 2, 3
MRK 14 HDAC4, 5, 6, 7, 8
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